What Happened
PDS, which engages in the development of multifunctional immunotherapic products, announced a modified clinical trial collaboration agreement with Merck & Co., Inc. MRK 1.07%.PDS’ lead Versamune-based immunotherapy PDS0101 will be evaluated in a Phase 2 trial in combination with the latter’s anti-PD-1 therapy Keytruda as a first-line treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16, or HPV16, infection.
The modification follows the recent FDA approval for Merck’s Keytruda as a monotherapy in patients whose tumors express PD-L1, or in combination with platinum and fluorouracil for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma.
PDS0101 is PDS’ proprietary clinical-stage immunotherapeutic administered by subcutaneous injection to treat HPV-associated cancers.
Why It’s Important
“We are honored to collaborate with Merck, a proven leader in the field of immuno-oncology to evaluate novel investigational combination therapies that have the potential to further improve the lives of cancer patients,” said Dr. Lauren Wood, chief medical officer at PDS, said in a statement.Recently released Phase 1 data that evaluated the PDS0101 monotherapy demonstrated unique in-vivo systemic induction of high levels of granzyme-b inducing HPV-specific killer T-cells associated with observed clinical responses in a majority of evaluable patients, according to PDS.
A lack of dose-limiting toxicities at all tested doses was observed, the company said.
The companies did not disclose the details of the collaboration.
What’s Next
PDS is the portfolio company of London-listed Netscientific Plc. On the collaboration news, Netscientific shares were rallying over 75% on the London Stock Exchange.https://www.benzinga.com/general/biotech/19/10/14539754/whats-behind-pds-biotechs-rally
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.